Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Junior Faculty Clinical Case Reports: Infectious Diseases (Banda Sea 2)
(ID)   Poster Numbers: 1245-1264

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: ID
Secondary Audiences: LF/LTX, PATH

Session Summary: This symposium will review the evidence and discuss the utility of detection of pathogens from surveillance bronchoscopies after lung transplantation. Evidence will be presented regarding the interpretation and treatment of positive culture results from surveillance bronchoscopy. We will review and analyze the management/treatment of bacteria, fungi, atypical mycobacteria and CMV in asymptomatic patients.

Chairs: Are Holm, MD and Stephanie M. Pouch, MD
 

8:00 AM	‘Critter Country’: Treatment and Eradication of Bacteria and Bacterial Biome Nicolas Mueller, MD, University Hospital Zurich, Zurich, Switzerland
8:15 AM	Q&A
8:20 AM	‘Fungal Frontierland’: Pathogens or Colonizers? Me-Linh Luong, MD, St. Luc Hospital, Montréal, QC, Canada
8:35 AM	Q&A
8:40 AM	‘Off Main Street’: Atypical Mycobacteria - What, When and How to Manage Fernanda Silveira, MD, University of Pittsburgh, Pittsburgh, PA, USA
8:55 AM	Q&A
9:00 AM	‘CMV Square’: Lung Transplant Recipients with CMV Positivity in a Bronchoscopy without CMV DNAemia Jutta K. Preiksaitis, MD, University of Alberta, Edmonton, AB, Canada
9:15 AM	Q&A
9:20 AM	‘Tomorrowland’: A Case-Based Approach to Managing Bronchoscopy Results Shalika B. Katugaha, MD, Inova Fairfax Hospital, Annandale, VA, USA
9:40 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: ID
Secondary Audiences: HTX, LTX, PEDS

Chairs: Valentina Stosor, MD and Saima Aslam, MD, MS
 

10:15 AM	(135) Routine Utilization of NAT Negative PHS Increased Risk Thoracic Organs Appears Safe and Effective in Increasing Organ Supply for Transplantation K. J. Gaj1, L. Irwin1, A. Leifer1, M. A. Villavicencio-Theoduloz2, K. Turvey1, G. D. Lewis3, C. Kotton4, D. A. D'Alessandro1. 1Transplant Surgery, Massachusetts General Hospital, Boston, MA, 2Transplant Surgery, Massachusetts General Hospital, Bosotn, MA, 3Advanced Heart Disease, Massachusetts General Hospital, Boston, MA, 4Infectious Disease Division, Massachusetts General Hospital, Boston, MA
10:30 AM	(136) Transplantation of NAT+HCV Donor Lungs into Non-Infected Recipients Followed by Treatment with Sofosbuvir/Velpatasvir (S/V) M. Cypel, J. Feld, L. G. Singer, N. Marks, I. Bahinskaya, M. Kuczynski, D. Kumar, M. Galasso, R. Ribeiro, J. Yeung, L. Donahoe, A. Pierre, M. de Perrot, K. Yasufuku, T. K. Waddell, S. Keshavjee, A. Humar, A. Humar. Toronto General Hospital, Toronto, ON, Canada
10:45 AM	(137) Preemptive Pan-Genotypic Direct Acting Antiviral Therapy in Donor HCV-Positive to Recipient HCV-Negative Cardiac Transplantation Produces Viral Clearance and is Associated with Favorable Outcomes G. D. Lewis, E. D. Bethea, K. Gaj, J. Gustafson, A. Dugal, K. Turvey, E. Coglianese, S. S. Thomas, C. Newton-Cheh, N. E. Ibrahim, W. D. Carlson, R. V. Shah, R. V. Shah, J. E. Ho, M. Nayor, J. K. Steiner, M. E. Afari, T. Lebeis, J. C. Madsen, M. A. Villavicencio-Theoduloz, R. T. Chung, D. A. D'Alessandro. Massachusetts General Hospital, Boston, MA
11:00 AM	(138) Magnitude of Recipient Viremia after Heart Transplantation from HCV Viremic Donors and Time to Clearance with Therapy C. G. Gidea1, A. Reyentovich1, D. Smith2, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami2. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
11:15 AM	(139) The Impact of Utilizing Hepatitis C Virus Nucleic Acid Test-Positive Donor Heart on Heart Transplant Waitlist Time Y. K. Gernhofer1, M. Brambatti2, B. H. Greenberg2, E. Adler2, S. Aslam3, V. Pretorius1. 1Cardiothoracic Surgery, UC San Diego, San Diego, CA, 2Cardiology, UC San Diego, San Diego, CA, 3Infectious Diseases, UC San Diego, San Diego, CA
11:30 AM	(140) The Impact of HCV Viremia in Heart Transplant Recipients from Donors with HCV Infection on Acute and Humoral Cellular Rejection C. G. Gidea1, N. Narula2, A. Reyentovich1, D. Smith3, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami3. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2Pathology, NYU Langone Medical Center, New York, NY, 3Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
11:45 AM	(141) Outcomes of Heart and Heart-Kidney Transplantation from Hepatitis C Virus (HCV) Positive Donors into HCV Negative Recipients S. Aslam1, I. Yumul2, M. Mariski1, V. Pretorius1, E. Adler1. 1University of California, San Diego, San Diego, CA, 2University of Iowa, Iowa City, IA

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: ID
Secondary Audiences: LF/LTX, PATH, PHARM

Session Summary: Fungal infections after thoracic transplantation are associated with high mortality. Prophylaxis and treatment come with various complications including drug-drug interactions, toxicities, treatment failure and emerging resistance. This symposium will provide insights regarding the epidemiology, prevention, diagnosis and treatment approaches to take when faced with the challenges of fungal infections in thoracic transplantation.

Chairs: Orla Morrissey, MD and Gregory A. Fishbein, MD
 

4:00 PM	Defining Fungal Infection: Not a TRIVIAL PURSUIT Erika D. Lease, MD, University of Washington, Seattle, WA, USA
4:15 PM	DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (PRO) John W. Baddley, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA
4:30 PM	DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (CON) Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada
4:45 PM	Don’t Be SORRY! Tips and Tricks for Managing Azole Antifungal Agents Tara Veasey, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA, USA
5:00 PM	Not a MONOPOLY: Antifungal Drug Administration Via the Inhaled Route Antonio B. Roman, MD, PhD, Hospital General Vall D'Hebron, Barcelona, Spain
5:15 PM	Are We in TROUBLE? Emergence of Azole-Resistant Molds Minh-Hong Nguyen, MD, University of Pittsburgh, Pittsburgh, PA, USA
5:30 PM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Infectious Diseases (Gardenia 2)
(ID, HTX, LTX, MCS)   Poster Numbers: 765-794

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: ID
Secondary Audience: MCS

Session Summary: Infections are a leading cause of death in VAD recipients, and are associated with morbidity, readmissions and healthcare costs. This symposium will focus on state of the art updates on the prevalence of VAD infections and their consequences including neurologic complications. Infection control and quality practices can impact the rate of infections. The recent ISHLT consensus document discussing the prevention and management of MCS infections will be reviewed.

Chairs: Saima Aslam, MD, MS and Jan D. Schmitto, MD, PhD, MBA
 

7:00 AM	What are the Consequences of a VAD Infection? Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA
7:15 AM	Q&A
7:20 AM	Infection Prevention for Patients with Mechanical Circulatory Support Margaret Hannan, MD, Mater Hospital, Dublin, Ireland
7:35 AM	Q&A
7:40 AM	Molecular Pathogenesis and Diagnostic Strategies for MCS Infections Anton Peleg, MD, PhD, MPH, The Alfred Hospital and Monash University, Melbourne, Australia
7:55 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: ID
Secondary Audience: MCS

Chairs: Margaret M. Hannan, MD and Christine E. Koval, MD
 

10:30 AM	(224) Increased Risk of Stroke and Death in Ventricular Assist Device Patients Varies by ISHLT Infection Category: An INTERMACS Analysis P. Shah1, S. E. Birk2, L. B. Cooper1, M. A. Psotka1, J. K. Kirklin3, S. D. Barnett1, S. B. Katugaha4, S. Phillips1, M. M. Looby5, F. D. Pagani6, J. A. Cowger7. 1Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, 2School of Public Health, George Washington University, Washington, DC, 3Cardiac Surgery, University of Alabama, Birmingham, AL, 4Transplant Infectious Diseases, Inova Heart and Vascular Institute, Falls Church, VA, 5Department of Pharmacy, Inova Heart and Vascular Institute, Falls Church, VA, 6Cardiac Surgery, University of Michigan, Ann Arbor, MI, 7Heart Failure and Transplantation, Henry Ford Hospital, Detroit, MI
10:45 AM	(225) Epidemiology, Outcomes, and Effects of Device Flow Type on Ventricular Assist Devices (VAD) Infections: An IMACS Registry Analysis R. Xie1, J. Cowger2, J. K. Kirklin1, M. M. Hannan3, D. J. Goldstein4, S. Aslam5. 1Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, 2Henry Ford Hospitals, Farmington Hills, MI, 3Mater Misericordiae University Hospital, Dublin, Ireland, 4Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, 5Division of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, CA
11:00 AM	(226) A Comprehensive In Vitro Evaluation of Medihoney as an Anti-Biofilm Agent in Preventing Ventricular Assist Device Driveline Infections Y. Qu1, D. McGiffin2, C. Kure2, J. McLean2, C. Duncan2, A. Y. Peleg1. 1Infectious Diseases, The Alfred Hospital and Monash University, Clayton, Australia, 2Cardiothoracic Surgery, The Alfred Hospital and Monash University, Melbourne, Australia
11:15 AM	(227) Efficacy of Pump Exchange with a Left Ventricular Assist Device Associated Infection L. Coyle, C. Gallagher, W. Cotts, P. Pappas, A. Tatooles. Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, IL
11:30 AM	(228) Primary versus Delayed Sternal Closure in Left Ventricular Assist Device Implantation Patients: Impact on Infection M. H. Akay1, M. Cakici1, M. Alagoz1, M. K. Patel1, M. K. Jezovnik1, M. Ilic1, I. Salas De Armas2, K. Rajagopal1, R. Radovancevic1, S. Kumar1, M. Jumean1, B. Kar1, I. D. Gregoric1. 1Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, 2Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center-Houston, Houston, TX
11:45 AM	(229) Comparing the Incidence of Surgical Site Infections(SSI) Using Narrow versus Broad-Spectrum Perioperative Antibiotic Prophylaxis in Mechanical Circulatory Support (MCS) Patients L. D. Lam1, M. Payne-Cardona2, M. Fang2, R. Herra2, E. Coria Mondragon2, C. Runyan1, J. Moriguchi3, J. A. Kobashigawa3, L. S. Czer3, F. Arabia4, R. Zabner5. 1Mechanical Circulatory Support, Cedars Sinai Comprehensive Transplant Center, Los Angeles, CA, 2University of California, School of Pharmacy, San Francisco, CA, 3Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 4Advanced Heart Program, Banner/University of Arizona, Phoenix, AZ, 5Infectious Disease, Cedars Sinai Health System, Los Angeles, CA
12:00 PM	(230) A Study of Infected Drivelines from Ventricular Assist Device Patients: The Presence of Microbial Biofilms and Micro-Gaps in the Driveline Tunnel Y. Qu1, D. McGiffin2, C. Hayward3, D. Robson3, C. Kure2, H. Thissen4, S. Marasco2, A. Zimmet2, J. Negri2, P. Jansz5, K. Dhital5, A. Peleg1. 1Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Australia, 2Cardiothoracic Surgery, The Alfred Hospital and Monash University, Melbourne, Australia, 3Department of Cardiology, St Vincent’s Public Hospital, Sydney, Darlinghurst, Australia, 4CSIRO, Melbourne, Australia, 5Cardiothoracic Surgery, St Vincent’s Public Hospital, Sydney, Darlinghurst, Australia

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: ID
Secondary Audience: HF/HTX, LF/LTX

Session Summary: This joint symposium with the Associação Brasileira de Transplante de Órgãos (ABTO: Brazilian Association of Organ Transplants) will provide the opportunity to exchange experiences between heart and lung transplant centers in Brazil and other centers around the world. Important topics regarding aspects of thoracic organ procurement in different countries and healthy systems as well as the regional variations in disease burden will be discussed.

Chairs: Fernanda Silveira, MD and Paulo M. Pego-Fernandes, MD, PhD
 

2:00 PM	The Largest Public Kidney Transplant Program in the World: What Lessons Should We Learn to Improve Thoracic Organ Transplantation? Jose Osmar Medina Pestana, MD, Hospital do Rim e Hipertensão of Universidade Federal de São Paulo, São Paulo, Brazil
2:15 PM	Few Potential Donors and One of the Largest (Lung) Transplant Systems of the World: How is it Possible? Jonathan Yeung, MD, Toronto General Hospital, Toronto, ON, Canada
2:30 PM	Tuberculosis and Thoracic Organ Transplantation: Pre- and Post-Transplant Management in Endemic Areas Luis Fernando Aranha Camargo, MD, PhD, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil
2:45 PM	Tuberculosis and Thoracic Organ Transplantation: Pre- and Post-Transplant Management in Non-Endemic Areas Amparo Sole, MD, Hospital Universitario La Fe, Valencia, Spain
3:00 PM	Heart Transplant and Chagas Disease: Lessons Learned After 30 Years of Experience Tania Mara Varejão Strabelli, MD, Heart Institute São Paulo Medical School, São Paulo, Brazil
3:05 PM	Highlights of Infectious Disease Jonathan M. Hand, MD, Ochsner Medical Center, New Orleans, LA, USA
2:15 PM	Chagas Disease and Heart Failure Management in Non-Endemic Areas Ricardo La Hoz, MD, UT Southwestern Medical Center, Dallas, TX, USA
2:15 PM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: ID
Secondary Audience: HTX, LTX, PEDS, PHARM

Chairs: Shahid Husain, MD, MS and Erik Verschuuren, MD, PhD
 

4:15 PM	(266) Pentraxin-3 Polymorphisms are Associated with Invasive Pulmonary Aspergillosis after Lung Transplantation A. Van Herck1, A. Sacreas1, T. Heigl1, J. Kaes1, A. Vanstapel1, S. E. Verleden1, D. Lambrechts2, B. M. Vanaudenaerde1, G. M. Verleden1, R. Vos1. 1Lung Transplant Unit, Department of Chronic Diseases, Metabolism & Ageing, University of Leuven, Leuven, Belgium, 2Laboratory of Translational Genetics (VIB Center for Cancer Biology), Department of Human Genetics, University of Leuven, Leuven, Belgium
4:30 PM	(267) Isavuconazonium Pharmacokinetic Interactions with Immunosuppression in Thoracic Transplant Recipients C. Burt1, J. Kozuch1, M. Mariski1, A. Feist1, K. Afshar2, G. Yung2, T. Floreth2, E. Golts3, S. Aslam4. 1Pharmacy, University of California San Diego Health, San Diego, CA, 2Pulmonology, University of California San Diego Health, San Diego, CA, 3Cardiothoracic Surgery, University of California San Diego Health, San Diego, CA, 4Infectious Diseases, University of California San Diego Health, San Diego, CA
4:45 PM	(268) A Comparison of Aspergillus Prophylaxis with Voriconazole versus Isavuconazole in Lung Transplant Recipients D. D. Nanayakkara1, E. Blodget1, S. Ganesh2. 1Infectious Diseases, University of Southern California, Los Angeles, CA, 2Pulmonary and Critical Care Medicine, University of Southern California, Los Angeles, CA
5:00 PM	(269) Quantiferon-CMV Guided Virostatic Prophylaxis after Heart Transplantation G. Poglajen, G. Zemljic, S. Frljak, R. Okrajšek, M. Šebeštjen, A. Cerar, V. Andročec, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia
5:15 PM	(270) Does the Use of Serum Ganciclovir Levels to Adjust Valganciclovir Dosing Prevent the Development of CMV Resistance in CMV Mismatched Heart Transplant Recipients? The Mid America Experience J. Linard1, C. Knutson1, R. Wells1, A. M. Borkon2, A. Kao3. 1Cardiac Transplant, Saint Luke's Mid America Heart Institute, Kansas City, MO, 2Cardiothoracic Surgery, Saint Luke's Mid America Heart Institute, Kansas City, MO, 3Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO
5:30 PM	(271) Use of Letermovir for CMV Prophylaxis or Treatment in Thoracic Organ Transplant Recipients C. S. King, S. S. Aryal, A. Cochrane, A. Brown, O. Shlobin, K. Ahmad, L. Marinak, M. Fregoso, J. Chun, S. Nathan, P. Shah, S. Desai, S. Katugaha. Inova Fairfax Hospital, Falls Church, VA
5:45 PM	(272) Impact of Prolonging CMV Prophylaxis in High-Risk (CMV D+/R-) Lung Transplant Recipients S. Herrera1, B. Khan2, S. Husain1, M. Binnie2, C. Chow2, T. Martinu2, C. Chaparro2, S. Keshavjee2, L. G. Singer2, J. Tikkanen2. 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: ID, BSTR
Secondary Audience: HTX, LTX, MCS, PATH, PEDS

Chairs: Tobias Deuse, MD, PhD and Ignacio Echenique, MD
 

6:15 PM	(525) Cytomegalovirus Infection among Pediatric Heart Transplant Recipients in the Current Era of Valganciclovir Prophylaxis: Impact on Post-Transplant Outcomes B. B. Das1, J. Niu2, P. K. Sue3, B. K. Prusty4. 1Joe DiMaggio Children's Heart Institute, Hollywood, FL, 2Memorial Healthcare System, Hollywood, FL, 3UT Southwestern Medical Center, Dallas, TX, 4University of Wuerzburg, Wuerzburg, Germany
6:20 PM	(526) KPC Klebsiella Identification Significantly Increases Risk of Bronchial Dehiscence in Lung Transplant Recipients J. Suh1, W. Yu1, S. Song1, J. Lee1, M. Park2, S. Kim2, J. Song2, S. Jeong2, H. Paik1. 1Thoracic Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, 2Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
6:25 PM	(527) Late Onset Invasive Pulmonary Aspergillosis in Lung Transplant Recipients Treated with a Preemptive/ Targeted Antifungal Therapy Strategy: 4 Year Follow Up S. Herrera1, A. Farooq1, S. Davoudi1, T. Martinu2, D. Kumar1, A. Humar1, C. Rotstein1, L. G. Singer2, S. Keshavjee2, S. Husain1. 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
6:30 PM	(528) Pre Transplant Interleukin 10 Levels are Higher in Lung Recipients with Post Transplant Infections L. Calahorra1, E. Sarmiento1, J. Cifrian2, C. Bravo3, R. Laporta4, M. Ussetti4, A. De Pablos5, A. Soler6, J. Carbone1. 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Pneumology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Pneumology, Hospital Universitario Valle de Hebron, Barcelona, Spain, 4Pneumology, Hospital Universitario Puerta de Hierro, Madrid, Spain, 5Pneumology, Hospital Universitario Doce de Octubre, Madrid, Spain, 6Pneumology, Hospital Universitario La Fe, Valencia, Spain
6:35 PM	(529) Correlation of ImmuKnow Assay Levels with Rejection and Infection after Heart Transplantation D. Nitta, T. Imamura, B. Chung, A. Nguyen, J. Raikhelkar, N. Sarswat, L. Lourenco, B. Smith, L. Holzhauser, G. Kim, I. Ebong, T. Fujino, N. Narang, C. Murks, T. Riley, J. Powers, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
6:40 PM	(530) IgG2 Insufficiency before Heart Transplantation as a Risk Factor of Early Deadly Infections J. Carbone1, J. Navarro1, I. Sousa2, E. Zatarain2, J. Fernandez-Yañez2, P. Muñoz3, M. Valerio3, E. Sarmiento1. 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Microbiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain,
6:45 PM	(531) Effective Reduction of Postoperative Infections through Routine Preoperative Decolonization with Chlorhexidine and Mupirocin Prior to Left Ventricular Assist Device Implantation S. George1, R. Leasure2, A. McGovern1, H. Setidadi1, D. A. Horstmanshof1. 1INTEGRIS Baptist Medical Center, Oklahoma City, OK, 2College of Nursing, University of Oklahoma, Oklahoma City, OK
6:50 PM	(532) Novel Bacteriophage Therapy for Treatment of Ventricular Assist Device Infections S. Aslam1, V. Pretorius1, E. Adler1, S. Lehman2, S. Morales2, A. Gaidamaka2, C. Furr2, F. Rosas2, K. Bishop-Lilly3, B. Biswas3, B. Sisson4, J. Fackler4, M. Trigg4, R. Schooley1. 1University of California, San Diego, San Diego, CA, 2AmpliPhi Biosciences, San Diego, CA, 3Naval Medical Research Center, Fort Detrick, MD, 4Adaptive Phage Therapeutics, Gaithersburg, MD
6:55 PM	(790) Role of Gallium-SPECT-CT in Predicting Outcomes of Patients with Ventricular Assist Device-Specific Percutaneous Driveline Infection Y. Kimura1, O. Seguchi1, H. Mochizuki1, K. Iwasaki1, K. Toda1, Y. Kumai1, K. Kuroda1, S. Nakajima1, T. Watanabe1, Y. Matsumoto2, S. Fukushima2, M. Yanase1, T. Fujita2, J. Kobayashi2, N. Fukushima1. 1Department of Transplant Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan, 2Department of Cardiac Surgery, National Cerebral and Cardiovascular Centre, Osaka, Japan